Oliver’s Law is a campaign launched by the family of Oliver Robinson following his death in November 2023. After being prescribed high-strength medical cannabis by a private clinic, despite a complex history of depression, dependency and psychiatric care, an inquest in January 2026 concluded that the prescription had contributed to his death. Oliver’s Law now calls for tighter safeguards around prescribing, particularly for patients with mental health conditions, including stronger clinical oversight, better communication with NHS services, and clearer regulatory controls to prevent similar cases in the future.
The emergence of Oliver’s Law marks a significant moment for the UK’s medical cannabis sector. Born from the death of Oliver Robinson, the campaign is already shaping conversations around prescribing standards, patient safety, and the future direction of access.
At its core, Oliver’s Law calls for tighter controls on private prescribing, particularly for patients with complex mental health histories. The question now facing the sector is not whether safeguards are needed, but whether the proposed response strikes the right balance between protection and access.
A system under scrutiny
Medical cannabis in the UK has operated within a largely private prescribing framework since rescheduling in 2018. While this has enabled access for thousands of patients, it has also created a system that is, at times, fragmented. Private clinics often operate separately from NHS care pathways. Communication between prescribers, GPs, and mental health services is not always consistent. Clinical approaches can vary between providers.
Oliver’s Law enters this landscape with a clear message: where systems are fragmented, risk can fall through the gaps.
The case for stronger safeguards
Supporters of Oliver’s Law argue that the sector has reached a point where greater clinical structure is both necessary and inevitable.
Key proposals associated with the campaign include:
- Improved information sharing between private clinics and NHS services
- More rigorous screening of patients, particularly those with psychiatric histories
- Greater accountability and oversight in prescribing practices
These measures align with established norms in other areas of medicine. For many, they represent a natural step in the evolution of a relatively young treatment pathway.
There is also a broader consideration. Public confidence in medical cannabis remains fragile. High-profile cases, particularly those involving harm, have the potential to shape regulatory attitudes for years to come. Strengthening safeguards may therefore be seen not only as a clinical necessity, but as a means of protecting the long-term legitimacy of the sector.
Marika Graham-Woods commented,
“Oliver’s Law raises legitimate and serious questions about patient safety, and those must be addressed through stronger clinical standards, better information sharing, and clearer accountability across the system. However, any response must be proportionate, evidence-led, and grounded in how medical cannabis is actually delivered in practice.
If safeguards are applied too broadly, particularly in areas such as mental health or NHS coordination, there is a real risk of creating barriers that restrict access, delay treatment, and ultimately push patients away from regulated care. The focus must be on improving the system, not unintentionally limiting it.”
The risk of overcorrection
At the same time, concerns are being raised across the industry that the response could go further than intended. One of the central issues is scope. If restrictions are applied too broadly, particularly around mental health, a significant proportion of current patients could find themselves excluded from treatment. This is not a theoretical risk. Chronic pain, anxiety, PTSD, and other conditions commonly seen in medical cannabis patients often overlap with mental health considerations.
There is also the question of NHS involvement. While greater integration is widely supported in principle, the NHS currently has limited capacity, training, and institutional alignment with cannabis-based medicines. Making NHS coordination a prerequisite for access could introduce delays or barriers that are difficult to overcome in practice. In this context, safeguards risk becoming bottlenecks.
The grey area: where policy meets reality
What makes Oliver’s Law particularly complex is that both sides of the argument hold validity. There were clearly areas of concern in the circumstances that led to the campaign. At the same time, the medical cannabis sector is still in the process of establishing consistent clinical frameworks.
The challenge lies in calibration. Too little change risks leaving genuine vulnerabilities unaddressed. Too much, applied too broadly, risks restricting access to the point where patients are driven back to unregulated sources. This is not unique to cannabis. It is a familiar tension in healthcare policy, where responses to individual cases can expand into system-wide reform.
A shifting narrative
Another notable feature of the current debate is the evolution of voices within it. Some early advocates for access have begun to emphasise the need for clearer boundaries between medical and non-medical use, and for stronger safeguards within clinical pathways. This reflects a broader shift from an access-led conversation to one increasingly shaped by safety and standardisation.
For policymakers, this convergence of perspectives carries weight. For the sector, it presents both a challenge and an opportunity to engage constructively.
What happens next
Oliver’s Law is not, at this stage, a defined piece of legislation. Its influence will likely be felt through a combination of regulatory guidance, clinical standards, and political pressure.
The direction it ultimately takes will depend on how key questions are answered:
- How is risk defined, particularly in relation to mental health?
- What level of NHS involvement is required, and how is that delivered in practice?
- How are safeguards implemented without disproportionately limiting access?
These are not simple questions, and they will require input from across the sector, including clinicians, patients, regulators, and industry bodies.
A sector at a crossroads
For the Cannabis Trades Association, the emergence of Oliver’s Law highlights a critical moment.
The sector has long advocated for safe, responsible, and compliant access to medical cannabis. That position remains unchanged. However, ensuring that safety measures are proportionate, evidence-based, and workable in practice will be essential.
The conversation now must move beyond polarised positions of “access versus restriction” and towards a more nuanced framework that recognises both patient need and clinical responsibility.
A clinician working across both NHS and private settings, who asked to remain anonymous, said:
‘Patient safety must always sit alongside clinical effectiveness. Medical cannabis is not without risk, particularly in patients with complex mental health histories, but neither is it inherently unsafe when prescribed appropriately.
What is needed is better training, clearer guidance, and improved communication between private clinics and NHS services so that care is joined up, informed, and consistent.
The aim should be to normalise good practice, not to create barriers that prevent patients from accessing treatment safely within a regulated framework.’
In that sense, Oliver’s Law is not simply a reaction to a single case. It is a test of how the UK chooses to shape the future of medical cannabis, and whether it can do so in a way that protects patients without losing sight of why access was established in the first place.
